May 3, 2007 - CMS, Inc., is currently testing and set to release Monaco, its next-generation Intensity Modulated Radiotherapy Treatment (IMRT) planning system, which in addition to a conventional dose-based optimization platform, will offer a biological model for more accurate and precise planning to account for tissue and volume-specific dose tolerances.
Monaco’s biological optimization model is designed to define the shape of the optimum dose distribution in normal tissues. The platform also provides a sensitivity analysis tool package and custom templates to reduce planning times. Other features include Monte Carlo and pencil beam dose algorithms; Smart Sequencing; constrained optimization with optional multicriterial solutions to limit dose delivery to affected organs; and Voxel definition controls.
In addition, the system is equipped with image fusion, contouring, simulation and plan review features. CMS anticipates it will receive FDA approval for Monaco in late 2007.
June 19, 2024 
